The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing the predictive value of ctDNA on relapse in patients with resected stage IB-IIIA NSCLC treated with adjuvant chemotherapy plus concomitant atezolizumab followed by atezolizumab: BTCRC LUN 19-396.
 
Fatemeh Ardeshir-Larijani
No Relationships to Disclose
 
Nisha Anjali Mohindra
Consulting or Advisory Role - AstraZeneca/MedImmune; G1 Therapeutics
Research Funding - Pfizer (Inst)
 
Anne M. Traynor
No Relationships to Disclose
 
Jyoti Malhotra
Consulting or Advisory Role - AstraZeneca; BeiGene; Blueprint Medicines; Mirati Therapeutics; OncoCyte; Sanofi
Research Funding - BeyondSpring Pharmaceuticals (Inst); Biohaven Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Daiichi Sankyo (Inst)
 
Elaine Shum
Consulting or Advisory Role - AstraZeneca; Genentech; Janssen
Research Funding - Delfi Diagnostics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Nektar
 
Patrick C. Ma
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences
Speakers' Bureau - AstraZeneca; Merck
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EpicentRx (Inst); Loxo (Inst); Merck (Inst); Tesaro (Inst)
 
Nasser H. Hanna
Honoraria - UpToDate
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck KGaA (Inst)